 |
PDBsum entry 2qxj
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of human kallikrein 7 in complex with suc-ala-ala- pro-phe-chloromethylketone and copper
|
|
Structure:
|
 |
Kallikrein-7. Chain: a. Synonym: hk7, stratum corneum chymotryptic enzyme, hscce, serine protease 6. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: klk7, prss6, scce. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Resolution:
|
 |
|
2.10Å
|
R-factor:
|
0.214
|
R-free:
|
0.248
|
|
|
Authors:
|
 |
M.Debela,P.Hess,V.Magdolen,N.M.Schechter,W.Bode,P.Goettig
|
Key ref:
|
 |
M.Debela
et al.
(2007).
Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.
Proc Natl Acad Sci U S A,
104,
16086-16091.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
11-Aug-07
|
Release date:
|
08-Jan-08
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P49862
(KLK7_HUMAN) -
Kallikrein-7 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
253 a.a.
224 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
104:16086-16091
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7.
|
|
M.Debela,
P.Hess,
V.Magdolen,
N.M.Schechter,
T.Steiner,
R.Huber,
W.Bode,
P.Goettig.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
hK7 or human stratum corneum chymotryptic enzyme belongs to the human tissue
kallikrein (hKs) serine proteinase family and is strongly expressed in the upper
layers of the epidermis. It participates in skin desquamation but is also
implicated in diverse skin diseases and is a potential biomarker of ovarian
cancer. We have solved x-ray structures of recombinant active hK7 at medium and
atomic resolution in the presence of the inhibitors
succinyl-Ala-Ala-Pro-Phe-chloromethyl ketone and Ala-Ala-Phe-chloromethyl
ketone. The most distinguishing features of hK7 are the short 70-80 loop and the
unique S1 pocket, which prefers P1 Tyr residues, as shown by kinetic data.
Similar to several other kallikreins, the enzyme activity is inhibited by Zn(2+)
and Cu(2+) at low micromolar concentrations. Biochemical analyses of the mutants
H99A and H41F confirm that only the metal-binding site at His(99) close to the
catalytic triad accounts for the noncompetitive Zn(2+) inhibition type.
Additionally, hK7 exhibits large positively charged surface patches,
representing putative exosites for prime side substrate recognition.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Fig. 4. Stick model of the modeled substrate
Glu-Ala-Leu-Tyr-Leu-Val, the catalytic triad and the backbone of
Gly^193, Ser^195, and Gly^216 of hK7[I] in stereo, including
hydrogen bonds as dotted lines. The S1 pocket is depicted as
transparent green surface according to volume calculations with
VOIDOO (41). The specificity for P1 Tyr is most likely conferred
by Asn^189 via hydrogen bonds from the carboxamide side chain to
an interconnecting water molecule and to the Tyr OH group,
respectively.
|
 |
Figure 5.
Fig. 5. The copper ions bound at His^99 and His^41
displayed as blue spheres surrounded by electron density of the
anomalous Fourier map in red (contour 5 ) in stereo. His^57 has
the capacity for liganding Cu1 and Cu2 by a side chain rotation
(His57*), requiring shifts of the ions, whereas the mutant H99A
proves that only the His^99 site is the structural basis for the
Zn^2+ and Cu^2+ inhibition of hK7.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Ishida-Yamamoto,
and
M.Kishibe
(2011).
Involvement of corneodesmosome degradation and lamellar granule transportation in the desquamation process.
|
| |
Med Mol Morphol,
44,
1-6.
|
 |
|
|
|
|
 |
A.Sukhwal,
M.Bhattacharyya,
and
S.Vishveshwara
(2011).
Network approach for capturing ligand-induced subtle global changes in protein structures.
|
| |
Acta Crystallogr D Biol Crystallogr,
67,
429-439.
|
 |
|
|
|
|
 |
H.Zhao,
Y.Dong,
J.Quan,
R.Smith,
A.Lam,
S.Weinstein,
J.Clements,
N.W.Johnson,
and
J.Gao
(2011).
Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma.
|
| |
Head Neck,
33,
566-572.
|
 |
|
|
|
|
 |
J.E.Swedberg,
S.J.de Veer,
and
J.M.Harris
(2010).
Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
|
| |
Biol Chem,
391,
357-374.
|
 |
|
|
|
|
 |
P.Goettig,
V.Magdolen,
and
H.Brandstetter
(2010).
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
|
| |
Biochimie,
92,
1546-1567.
|
 |
|
|
|
|
 |
J.A.Clements
(2008).
Reflections on the tissue kallikrein and kallikrein-related peptidase family - from mice to men - what have we learnt in the last two decades?
|
| |
Biol Chem,
389,
1447-1454.
|
 |
|
|
|
|
 |
M.Debela,
N.Beaufort,
V.Magdolen,
N.M.Schechter,
C.S.Craik,
M.Schmitt,
W.Bode,
and
P.Goettig
(2008).
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
|
| |
Biol Chem,
389,
623-632.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |